RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shanghai Henlius Biotech Stock

Shanghai Henlius Biotech ROCE 2024

Shanghai Henlius Biotech ROCE

0.31

Ticker

2696.HK

ISIN

CNE100003N76

In 2024, Shanghai Henlius Biotech's return on capital employed (ROCE) was 0.31, a -180.46% increase from the -0.38 ROCE in the previous year.

Shanghai Henlius Biotech Aktienanalyse

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Shanghai Henlius Biotech's Return on Capital Employed (ROCE)

Shanghai Henlius Biotech's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Shanghai Henlius Biotech's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Shanghai Henlius Biotech's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Shanghai Henlius Biotech’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Shanghai Henlius Biotech stock

What is the ROCE (Return on Capital Employed) of Shanghai Henlius Biotech this year?

The ROCE of Shanghai Henlius Biotech is 0.31 undefined this year.

How has the ROCE (Return on Capital Employed) of Shanghai Henlius Biotech developed compared to the previous year?

The ROCE of Shanghai Henlius Biotech has increased by -180.46% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Shanghai Henlius Biotech?

A high Return on Capital Employed (ROCE) indicates that Shanghai Henlius Biotech has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Shanghai Henlius Biotech?

A low ROCE (Return on Capital Employed) can indicate that Shanghai Henlius Biotech has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Shanghai Henlius Biotech impact the company?

An increase in the ROCE of Shanghai Henlius Biotech can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Shanghai Henlius Biotech affect the company?

A decrease in ROCE of Shanghai Henlius Biotech can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Shanghai Henlius Biotech?

Some factors that can affect Shanghai Henlius Biotech's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Shanghai Henlius Biotech so important for investors?

The ROCE of Shanghai Henlius Biotech is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Shanghai Henlius Biotech take to improve the ROCE?

To improve the ROCE, Shanghai Henlius Biotech can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Shanghai Henlius Biotech pay?

Over the past 12 months, Shanghai Henlius Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Henlius Biotech is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Henlius Biotech?

The current dividend yield of Shanghai Henlius Biotech is .

When does Shanghai Henlius Biotech pay dividends?

Shanghai Henlius Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Henlius Biotech?

Shanghai Henlius Biotech paid dividends every year for the past 0 years.

What is the dividend of Shanghai Henlius Biotech?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Henlius Biotech located?

Shanghai Henlius Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Henlius Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Henlius Biotech from 7/31/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Shanghai Henlius Biotech pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Shanghai Henlius Biotech in the year 2023?

In the year 2023, Shanghai Henlius Biotech distributed 0 CNY as dividends.

In which currency does Shanghai Henlius Biotech pay out the dividend?

The dividends of Shanghai Henlius Biotech are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Henlius Biotech

Our stock analysis for Shanghai Henlius Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Henlius Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.